Screener
Organogenesis Holdings Inc. ORGO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Organogenesis Holdings Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Organogenesis Holdings Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338049
FAQ
- What is Organogenesis Holdings Inc.'s cash & equivalents?
- Organogenesis Holdings Inc. (ORGO) reported cash & equivalents of $46.1M in Q2 2026.
- How has Organogenesis Holdings Inc.'s cash & equivalents changed year-over-year?
- Organogenesis Holdings Inc.'s cash & equivalents decreased by 36.9% year-over-year, from $73.08M to $46.1M.
- What is the long-term trend for Organogenesis Holdings Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Organogenesis Holdings Inc.'s cash & equivalents has grown at a 2.1% compound annual growth rate (CAGR), from $84.39M to $93.68M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Organogenesis Holdings Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude